Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner to organizations ... May 14-16, 2014 at the Global Center for Health ... This is the premier industry event for ... open innovation. Participants will learn how world-changing innovation is ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... NEW YORK, Jan. 11, 2011 Reportlinker.com announces ... in its catalogue: Innovative Drug ... http://www.reportlinker.com/p0359990/Innovative-Drug-Discovery-in-Emerging-Markets.html Introduction Emerging markets ... pharmaceutical industry, but it has been unclear the ...
... (Nasdaq: STXS ) announces the first successful ... as the company received CE Mark for this latest ... with the Vdrive system, Tamas Szili-Torok, MD, Ph.D., from ... Center in The Netherlands, successfully treated atrial fibrillation in ...
Cached Medicine Technology:Reportlinker Adds Innovative Drug Discovery in Emerging Markets 2Reportlinker Adds Innovative Drug Discovery in Emerging Markets 3Stereotaxis Announces CE Mark and First Human Case for Vdrive™ 2Stereotaxis Announces CE Mark and First Human Case for Vdrive™ 3
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... help because of illnesses related to alcohol abuse seem to ... ,Current official statistics show that emergency wards in ... and emergencies caused due to drunkenness since 1997. ... also have doubled, reported NHS since 1997, accounting for more ...
... up for pricey wine appreciation classes to parse the subtle ... and the black currant// scent of a cabernet sauvignon. Just ... quickly help you become a modest oenophile. It’s up to ... ,A new study by Northwestern University researchers shows that the ...
... official journal of the American Neurological Association, examined brain ... devastated in FTD//. ,Von Economo neurons (VENs) ... evolved in a select group of socially complex species: ... Across species, VENs are localized to frontal brain regions ...
... reach for aspirin. What is giving researchers a headache ... whether there is another form on top of the long-known ... India seems to have solved this controversial puzzle: yes, there ... pure form. ,“The two crystalline forms of ...
... the risk to develop stroke than men, discovered a British study ... of blood to the brain or due to tiny blockages in ... who suffered strokes had 40% more chance to have a family ... chances in those women having mothers who also had a history ...
... finds that 95 percent of Americans have pre marital sex-sex ... American men //and women as far back as the 1940 ... spending hundreds of millions of dollars advising young adults to ... One official disagreed and opined that even if the programs ...
Cached Medicine News:Health News:Researchers Discover How We Differentiate Smells 2Health News:A Study Finds VENs Devastated in FTD 2Health News:Does Aspirin Crystallize? 2
... is a premium agarose used for isolating ... agarose produces clear sharp bands, with no ... of UltraClean Forensic Agarose is tested and ... RNase activity and DNA contamination. ...
... is specifically formulated for high resolution of ... bp. This standard melting temperature agarose can ... 10 bp difference in size. UltraPure™ ... structure for better handling and improved clarity ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... solid. Highly purified non-ionic fraction of agar. ... very low concentrations. Can be mounted on ... films are elastic and durable and show ... either protein or lipoprotein dyes. Contaminants: ...
Medicine Products: